ReviewJournal of analytical methods in chemistry2026
Breath by Breath: Navigating the Landscape of Exhaled Breath in Clinical Research and Prospects for the Future.
Review in Journal of analytical methods in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Breath by Breath: Navigating the Landscape of Exhaled Breath in Clinical Research and Prospects for the Future.Journal of analytical methods in chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exhaled breath analysis (EBA) has evolved as a noninvasive diagnostic technique with enormous promise in healthcare. The development in this area is based on the concept that the breathalyzers employed to measure the alcohol concentration in the blood can be utilized to evaluate health by analyzing the intricate chemical makeup of exhaled breath, which includes various volatile organic compounds (VOCs). Breath analysis could be the driver of personalized medicine and used in early disease identification as it involves the detection of a variety of disease-specific biomarkers. In diagnostics, EBA offers a noninvasive procedure of illness identification and monitoring. This approach allows for early detection, personalized treatment options, and therapeutic monitoring by detecting disease-specific VOC biomarkers such as acetone in diabetes and ethane in lipid peroxidation. Also, EBA can measure environmental exposures such as air pollution or occupational dangers. By identifying VOCs from various sources, researchers can measure exposure levels and assess related health hazards. Advances in the analytical methods, including mass spectrometry, gas chromatography, and sensor arrays made it possible to quantify and identify VOCs in exhaled air with high sensitivity and precision. This review focuses on the biomarkers present in breath and their role in identifying diseases. It covers the essential compounds found in breath and their biochemical processes. Furthermore, an in-depth examination of different methods for identifying biomarkers in breath and the factors influencing VOC concentrations, including age, storage conditions, external sources, and the difference between dead space air and alveolar air, has been discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.